ALGINATE LIQUID PREPARATION
    1.
    发明公开

    公开(公告)号:US20240226137A1

    公开(公告)日:2024-07-11

    申请号:US18618489

    申请日:2024-03-27

    IPC分类号: A61K31/734 A61K9/08 A61K47/02

    CPC分类号: A61K31/734 A61K9/08 A61K47/02

    摘要: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.

    FREEZE-DRIED ALGINIC ACID PREPARATION
    4.
    发明公开

    公开(公告)号:US20230210777A1

    公开(公告)日:2023-07-06

    申请号:US18120596

    申请日:2023-03-13

    IPC分类号: C08B37/00

    CPC分类号: C08B37/0084

    摘要: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

    Crystals of tetrahydronaphthyl urea derivative

    公开(公告)号:US11325895B2

    公开(公告)日:2022-05-10

    申请号:US16647223

    申请日:2018-09-13

    IPC分类号: C07D401/04

    摘要: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.

    NOVEL PHOTOCROSSLINKABLE ALGINIC ACID DERIVATIVE

    公开(公告)号:US20210380727A1

    公开(公告)日:2021-12-09

    申请号:US16976027

    申请日:2019-02-27

    IPC分类号: C08B37/00

    摘要: The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided.

    Nerve regeneration-inducing material

    公开(公告)号:US11052174B2

    公开(公告)日:2021-07-06

    申请号:US16083600

    申请日:2017-03-14

    摘要: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.